The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BCAB | -37.47% | N/A | N/A | -97% |
| S&P | +11% | +85.61% | +13.15% | +78% |
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.06M | -100.5% |
| Gross Margin | 97.93% | 0.0% |
| Market Cap | $40.39M | -52.5% |
| Market Cap / Employee | $0.53M | 0.0% |
| Employees | 76 | 16.9% |
| Net Income | -$15.78M | -49.0% |
| EBITDA | -$13.73M | -24.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.32M | -85.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.01M | 0.0% |
| Short Term Debt | $1.17M | -6.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -165.61% | -89.0% |
| Return On Invested Capital | -156.30% | -110.4% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$16.65M | 46.0% |
| Operating Free Cash Flow | -$9.88M | -92.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.24 | 1.41 | 42.26 | -2.41 | -165.12% |
| Price to Sales | 7.73 | 2.68 | 1.84 | 2.11 | - |
| Price to Tangible Book Value | 1.24 | 1.41 | 42.28 | -2.41 | -165.12% |
| Enterprise Value to EBITDA | 1.17 | 0.67 | -0.59 | -2.79 | 3.24% |
| Return on Equity | -139.1% | -164.3% | -246.2% | -813.9% | 506.72% |
| Total Debt | $0.84M | $0.55M | $6.05M | $6.18M | 394.08% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
